Recursion Pharmaceuticals, Inc. RXRX Business Segments — Other income (loss), net
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NonoperatingIncomeExpense.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — other income (loss), net of $6.4M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net increased by 156.7% year-over-year, from -$11.28M to $6.4M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — other income (loss), net has grown at a -19.7% compound annual growth rate (CAGR), from $6.25M to $3.24M.
- What does business segments — other income (loss), net mean?
- Includes non-operating financial results, such as interest income, investment gains or losses, and other peripheral financial activities. This metric helps isolate the impact of non-core financial events from the segment's primary operational performance.